Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology, running from February 5–9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology, running from February 5–9, 2022. The company will present findings on its investigational gene therapies, DB-OTO and AAV.104, aimed at restoring hearing in patients with specific gene mutations. The presentations include two podium talks and two virtual posters, highlighting advancements in treatments for congenital hearing loss and auditory processing disorders.
Details
News Market Reaction – DBTX
The recorded move for DBTX in the trading session of this news was -0.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held virtually February 5–9, 2022.
The Company will present two podium presentations and two virtual posters focusing on its lead investigational gene therapy, DB-OTO, being developed to restore hearing to individuals with a mutation in the otoferlin gene, and AAV.104, a gene therapy program designed to restore hearing to individuals with a mutation in the stereocilin gene.
Podium Presentations
Podium 11.7 | Development of an AAV-Based Gene Therapy for Children With Congenital Hearing Loss Due to Otoferlin Deficiency (DB-OTO)
Presenter: Jonathon Whitton, Ph.D., Au.D.
Session Title: Inner Ear Therapeutics
Date & Time: Sunday, February 6, 4:30–4:45 p.m. ET
Podium 28.3 | Dual Vector Gene Therapy Rescues Hearing in a Stereocilin Deficient Mouse Model
Presenter: Lars Becker, Ph.D.
Session Title: Non-Auditory Factors in Auditory Processing
Date & Time: Tuesday, February 8, 3:30–3:45 p.m. ET
Virtual Poster Presentations
299 | Adeno Associated Virus Transgenes Under Control of the SLC6A14 Proximal Promoter Drive Vestibular Supporting Cell-Specific Transgene Expression
298 | Identification of GJB2’s Upstream Regulatory Elements Facilitates Design of Safe, Precision AAVs and Recovery of Hearing in a GJB2-Deficient Mouse Model
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.
Investor Contact:
Julie Seidel
Stern IR, Inc.
212-362-1200
Julie.seidel@sternir.com
Media Contact:
Chris Railey
Ten Bridge Communications
617-834-0936
chris@tenbridgecommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.